The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.
Voluntary participation and signed informed consent form;
Age ≥18 years;
Eastern Cooperative Oncology Group performance status 0-1;
The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer;
Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment；
Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection；
Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure;
Major surgical procedures had been performed within 4 weeks before consent was obtained；